Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

NCT02007629 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension, Pulmonary

Interventions

DRUG: Riociguat (Adempas, BAY63-2521)

Sponsor

Bayer